BioWorld

June 13, 2002

BIO 2002 Conference Concludes; Washington Is Industry's Next Stop

TORONTO - The third and final day of the Biotechnology Industry Organization's International Biotechnology Convention & Exhibition began with rain. Read More

Panel: Confess About Failures, Then Push Research Onward

Deadly Gut Bug, Enterococcus faecalis, Hints At Drug Targets Against Antibiotic Resistance

ISTA Plans To Raise $30M, Start Vitrase NDA This Year

FBI Nabs ImClone's Waksal; $10M Bond On SEC Charges

Bush Signs New PDUFA With Anti-Terrorism Bill

Millennium's Velcade Entering Phase III For Multiple Myeloma

Antibodies Charging Ahead With Smart' New Methods

Brownback May Compromise On Senate Cloning Measure

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for June 26, 2026.

Illustration for mutations in the DNA leading to brain diseases or neurodegenerative disorders

ENCALS 2026: From genetics to advancing strategies against ALS

BioWorld Science

Amyotrophic lateral sclerosis (ALS)-associated genes provide direct therapeutic targets and reveal pathways that can be used to develop treatments that counteract...

Next wave of BCI firms builds on pioneers to tackle challenges

BioWorld

With the pace of neurotechnology development accelerating, a wave of brain-computer interface (BCI) companies is emerging on the heels of the pioneers. In the...

Boehringer Ingelheim identifies new mGlu3 receptor agonists

BioWorld Science

Boehringer Ingelheim Pharma GmbH & Co. KG and Vanderbilt University have discovered new dihydrobenzoxazine compounds acting as metabotropic glutamate mGlu3...

GT-02897 exerts efficacy in preclinical multiple myeloma

BioWorld Science

Investigators from the Karl Landsteiner University aimed to evaluate the therapeutic potential of a novel CDK9 inhibitor/degrader, GT-02897, for the potential...